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Abstract
Background: We conducted the present study to investigate the therapeutic effects of a combination
treatment of alfacalcidol (ALF) and risedronate (RIS) on the bone mechanical properties of bone and
calcium (Ca) metabolism using an ovariectomized (OVX) rat model of osteoporosis.
Methods: Female Wistar rats were OVX- or sham-operated at 40 weeks of age. Twelve weeks post-
surgery, rats were randomized into seven groups: 1) sham + vehicle, 2) OVX + vehicle, 3) OVX + ALF
0.025 μg/kg/day, 4) OVX + ALF 0.05 μg, 5) OVX + RIS 0.3 mg, 6) OVX + RIS 3.0 mg, 7) OVX + ALF 0.025
μg + RIS 0.3 mg. Each drug was administered orally five times a week for 12 weeks. After treatment, we
evaluated the mechanical properties of the lumbar vertebra and femoral midshaft. In the lumbar vertebra,
structural and material analyses were performed using micro-computed tomography (micro-CT) and
microbeam X-ray diffraction (micro-XRD), respectively. Biochemical markers in serum and urine were
also determined.
Results: (1) With respect to improvement in the mechanical strength of the lumbar spine and the femoral
midshaft, the combination treatment of ALF and RIS at their sub-therapeutic doses was more effective than
each administered as a monotherapy; (2) In the suppression of bone resorption and the amelioration of
microstructural parameters, the effects of ALF and RIS were considered to be independent and additive;
(3) The improvement of material properties, such as microstructural parameters and the biological apatite
(Bap) c-axis orientation, contributed to the reinforcement of spinal strength; and (4) The combination
treatment of ALF and RIS normalized urinary Ca excretion, suggesting that this treatment ameliorated the
changes in Ca metabolism.
Conclusion: These results demonstrate that the combination treatment of ALF and RIS at their sub-
therapeutic doses can improve the mechanical properties of the spine as well as the femur and ameliorate
changes in Ca metabolism in an animal model of osteoporosis, suggesting that the combination treatment
of ALF and RIS has a therapeutic advantage over each monotherapy for the treatment of osteoporosis.
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Background
The incidence of osteoporosis is increasing rapidly in the
elderly population. Osteoporosis is a degenerative disease
characterized by reduced bone mass and deterioration of
bone microstructures which increases the risk of fracture
[1]. Osteoporosis is divided into two types: postmenopau-
sal osteoporosis and senile osteoporosis. The causes of
postmenopausal osteoporosis are accelerated bone
resorption and systemic calcium (Ca) imbalance due to
menopause-induced estrogen deficiency. In contrast,
senile osteoporosis is attributed to the age-related reduc-
tion of osteogenesis, insufficient Ca intake, reduced Ca
absorption, and Ca imbalance due to hyperparathy-
roidism caused by vitamin D deficiency [2].
Alfacalcidol [1α(OH)D3; ALF] is a prodrug of active vita-
min D3, a Ca-regulating hormone, and is frequently used
in several countries to treat osteoporosis. There are some
studies that have shown ALF to be effective as an anti-oste-
oporotic agent [3,4], although high doses of ALF have
been associated with adverse drug reactions such as hyper-
calciuria and hypercalcemia. Ovariectomy increases bone
turnover in rats by accelerating resorption and formation
of bone, and, because bone resorption is dominant, bone
mass eventually decreases. Hence, ovariectomized (OVX)
rats have been used widely as an animal model of post-
menopausal osteoporosis [5]. Previously, we studied the
preventive therapy of administering ALF to rats immedi-
ately after ovariectomy and found that ALF sustained or
increased bone mass by suppressing bone resorption
while maintaining bone formation, and, in addition,
facilitating the absorption of Ca in the intestine [6].
Risedronate (RIS) is a third-generation bisphosphonate
(sodium risedronate hydrate), and like alendronate
(ALN), is a potent bone resorption inhibitor that is used
clinically to treat osteoporosis [7]. Recently, it has been
reported that, although RIS had a role in mineralization,
it did not change bone mass and bone structure markedly
[8-10]. It has also been shown that in postmenopausal
osteoporosis, three- and five-year treatment with RIS
increases the degree and homogeneity of mineralization
without producing hypermineralization [11], while
Boivin GY et al. have reported that long-term treatment
with ALN prolongs the viability of bone structure units
(BSU) and prolongs the duration of secondary minerali-
zation [12]. Depending on the bisphosphonate used there
is a risk of adverse drug reactions, such as upper gastroin-
testinal tract bleeding, and complicated prescriptions can
lead to low compliance.
Based on the present definition of osteoporosis, both den-
sity and quality are important for bone strength [13-15].
Although the definition of bone quality remains contro-
versial, it is thought to encompass both structural and
material properties of bone. In recent reports, the biolog-
ical apatite (Bap) c-axis orientation was analyzed by
microbeam X-ray diffraction (micro-XRD) as a useful
material parameter for bone quality in evaluating
mechanical function, in addition to in vivo stress distribu-
tion and bone formation processes [16-18]. BAp c-axis has
been revealed to be in close alignment with the direction
of collagen fibers [19,20], and moreover, Bap has been
shown to crystallize under an anisotropic hexagonal lat-
tice, with the mechanical properties of the BAp crystallite
depending on the crystal orientation [21]. According to
micro-XRD analysis, preferential alignment of the BAp c-
axis varies sensitively depending on the portion, bone
shape, and in vivo stress distribution [16]. The preferen-
tial degree of BAp c-axis orientation relating to the colla-
gen fiber direction also changes according to bone
condition with ageing, bone diseases and severity, bone
regeneration, and gene defects, etc. [17]. In spite of a case
using neutron scattering, for example, the degree of pref-
erential alignment of the BAp c-axis changes with age due
to changes in stress at different times in a human's life,
resulting in the local maximum at three years old in fem-
ora along the bone longitudinal axis [22]. A more recent
micro-XRD study showed a negative correlation between
the degree of BAp orientation and the mineral apposition
rate (MAR) in rat femora [18]. In a pathological state, for
example, the degree of osteoporosis accelerates causing
the degree of BAp orientation in mice femora to decrease
[23]. Thus, the degree of BAp orientation seems to be one
of the important indices in evaluating in vivo stress distri-
bution, nano-scale microstructure and related mechanical
functions of the damaged bone, and in diagnosing bone
diseases.
The objective of this study was to clarify the effects of ALF
and RIS combination treatment at their respective sub-
therapeutic doses on ameliorating changes in bone
mechanical properties and bone metabolism. Our
hypothesis was that the combined treatment of ALF and
RIS may allow significant increases in bone strength due
to suppression of bone resorption compared with each
administered as a monotherapy. To test this hypothesis,
aged OVX rats were treated 5 times a week with vehicle,
ALF (0.025, 0.05 μg/kg), RIS (0.3, 3 mg/kg), or ALF (0.025
μg/kg) combined with RIS (0.3 mg/kg) for 12 weeks. We
assessed the parameters as follows; (1) the mechanical
properties in lumbar spine and femoral midshaft; (2), the
bone density and BAp axis orientation in the cortical
region of lumbar vertebra and microstructural parameters
in trabecular bone of lumbar vertebra, and (3) urinary
deoxypyridinoline (DPD) excretion as a bone resorption
marker and serum and urinary biochemical parameters.BMC Musculoskeletal Disorders 2009, 10:66 http://www.biomedcentral.com/1471-2474/10/66
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Methods
Reagents
ALF, synthesized at Chugai Pharmaceutical Co., Ltd.
(Gotemba, Japan), was dissolved in medium-chain trig-
lyceride (MCT) and diluted to given concentrations. Com-
mercially available RIS, purchased from LKT Laboratories,
Inc. (Minnesota, USA), was dissolved in sterile physiolog-
ical saline and diluted to given concentrations. Both solu-
tions were administered orally at a dose of 1 mL/kg body
weight.
Experimental Design
All animal studies were performed according to Chugai
Pharmaceutical's ethical guidelines for animal care, and
the experimental protocols were approved by the Animal
Care Committee of the institution. Eleven-month-old
female Wistar-Imamichi rats (n = 55) were purchased
from the Imamichi Institute for Animal Reproduction
(Ibaraki, Japan). The rats were kept in individual stainless
steel wire cages, and were allowed free access to commer-
cial standard rodent chow (CE-2; CLEA Japan, Inc. Tokyo,
Japan) and tap water. The bone mineral density (BMD) of
lumbar vertebrae (L2-L4) was measured in all rats by in
vivo scanning using DXA analysis (DCS-600, Aloka,
Japan). Based on their spinal BMD, the rats were divided
into seven groups with roughly equal average BMD. In all
7 groups, an incision was made in the skin of the back
under etherization. Bilateral ovariectomy was performed
in six groups; in the remaining group (the sham-operation
group), only the skin incision was made. At 12 weeks after
surgery, the spinal BMDs of rats in the OVX groups was
measured, and the rats were divided into the following six
groups with almost the same average BMD: a OVX-vehicle
control (OVX) group, a 0.025 μg/kg ALF-treated (ALF-L)
group, a 0.05 μg/kg ALF-treated (ALF-H) group, a 0.3 mg/
kg RIS-treated (RIS-L) group, a 3.0 mg/kg RIS-treated (RIS-
H) group, and a 0.025 μg/kg ALF and 0.3 mg/kg RIS com-
bination-treated (ALF-L + RIS-L) group. ALF and RIS were
administered orally once daily, five times a week. ALF was
administered between 8:00 and 10:00, and RIS was
administered between 14:00 and 16:00. The body weight
of each rat was measured weekly, and the volume of drug
or vehicle administered was calculated based on the most
recent body weight measurement. At 12 weeks after the
administration of drug or vehicle, all rats were necropsied.
The rats were fasted for 24 hours after the final adminis-
tration, and a 24-hour urine sample was collected and
stored frozen at -70°C. At the time of necropsy, each rat
was etherized, a blood sample was collected from the jug-
ular vein, and the serum was isolated and stored frozen at
-70°C. After the blood sample was collected, the rats were
bled to death, and the lumbar vertebrae (L4-L5) and bilat-
eral femurs were excised. The fifth lumbar vertebra (L5)
and left femur, which were used to measure the mechani-
cal strength, were stored frozen at -70°C, and the other
vertebra (L4), which was used to measure the BMD and
micro-XRD, was fixed in 70% ethanol.
Biochemical Analysis
Serum concentrations of Ca and inorganic phosphorus
(P) were measured using an autoanalyzer (Hitachi 7170;
Hitachi Co., Ltd., Tokyo, Japan). Urinary Ca, P and creat-
inine (CRE) were also measured using the autoanalyzer.
Urinary DPD excretion was measured using an OSTE-
OLINKS-DPD EIA kit (Sumitomo Seiyaku Biomedical
Co., Ltd., Osaka, Japan), and the data were corrected for
the urinary CRE concentration.
Measurement of Mechanical Properties
Using a mechanical strength analyzer (TK-252CC;
Muromachi Kikai Co., Ltd., Tokyo, Japan), the mechanical
strength of the lumbar vertebra (L5) and left femur was
measured using a compression test [24] and a three-point
bending test [25], respectively.
For the compression test, the planoparallel surfaces were
obtained by removing the cranial and caudal ends of the
vertebral specimen. From the vertebral body, a central cyl-
inder with planoparallel ends and a height of approxi-
mately 5 mm was obtained. A compression force was
applied to the specimen in the cranio-caudal direction
using a steel disk at a deformation rate of 2.5 mm/min.
The ultimate compressive load (N), the stiffness (N/mm),
and the energy (mJ) were calculated as the mechanical
properties directly from the load-displacement curve.
For the three-point bending test, the left femur was placed
on a special holding device with supports located 12 mm
apart. A bending force was applied with the cross head at
a speed of 20 mm/min, until a fracture occurred. From the
load-displacement curve, the ultimate compressive load
(N), the stiffness (N/mm), and the energy (mJ) were
obtained.
Structural Analysis using Micro-computed Tomography 
(micro-CT)
In order to investigate the additive effects of ALF and RIS
combination treatment on the trabeculae in the cancel-
lous tissue of the L5 vertebral body, three-dimensional
trabecular analysis was performed by micro-CT (μCT40;
Scanco Medical, Zurich, Switzerland). The μCT40 is
equipped with a microfocus X-ray tube with a focal spot
of 10 μm, producing a fan beam that is detected by a
charge-couple device array with a turntable that can be
shifted automatically in the axial direction. The filtered
40-kVp X-ray spectrum peaks at 25 keV, allowing excellent
bone-versus-marrow contrast. The whole spinal body was
scanned in 250 slices (thickness, 13 μm) in the dorsoven-
tral direction. On the original three-dimensional images,
morphometric indices were directly determined from theBMC Musculoskeletal Disorders 2009, 10:66 http://www.biomedcentral.com/1471-2474/10/66
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binarized volume of interest (VOI) [26]. Three-dimen-
sional reconstruction of bone was performed using the tri-
angulation algorithm. The volume of trabecular bone (BV,
mm3) was calculated using tetrahedrons corresponding to
the enclosed volume of the triangulated surface. Bone sur-
face area (BS) was calculated using the Marching Cubes
method to triangulate the surface of the mineralized bone
phase. The total tissue volume (TV, mm3) is the volume of
the whole examined sample. To compare between sam-
ples of different sizes, we normalized values such as the
bone volume fraction (BV/TV, %) and trabecular bone
surface density (BS/BV, %). Using the original application
and the method described by Hildebrand et al, we directly
measured the following histomorphometric parameters
on three-dimensional images, not using the parallel plate
model: trabecular number (Tb.N,/mm), trabecular thick-
ness (Tb.Th, μm), and trabecular separation (Tb.Sp, μm)
[27]. Thus, Tb.Th, Tb.Sp, and Tb.N were model-independ-
ent indices, and were not biased by eventual deviations of
the actual structure.
Measurement of BMD using Peripheral Quantitative 
Computed Tomography (pQCT)
The BMD (mg/cm3) of the ventral cortical portion at the
center of L4 was analyzed by the pQCT method using XCT
research SA (Stratec Medizintechnik Pforzheim, Ger-
many) [28,29] in a volume of 240 × 240 × 460 μm3, where
the surface area (240 × 240 μm2) corresponded to the
same region on which the micro-XRD measurement was
performed. Figure 1 shows the regions of pQCT BMD and
BAp axis measurements. The volume for each voxel reso-
lution was 80 × 80 × 460 μm3.
Material Analysis using Microbeam X-ray Diffraction 
(micro-XRD)
Preferential alignment of the BAp c-axis correlating to the
collagen arrangement is a useful parameter for evaluating
in vivo stress distribution, the process of bone formation
and growth, and mechanical function in bone tissues
[16]. In order to understand the additive effects of ALF
and RIS combination treatment on preferential alignment
of the BAp c-axis correlating to the collagen arrangement
as a bone material parameter in the cortical portion of the
L4 vertebral body, quantitative crystallographic analysis
of preferential BAp orientation was performed using a
microbeam X-ray diffractometer system (micro-XRD; Mac
Science, M18XHF22-SR, Tokyo, Japan). Cu-Kα radiation
was generated at a tube voltage of 90 kV and a tube current
of 40 mA. Diffracted beams were detected with a curved
position sensitive proportional X-ray counter (PSPC). The
incident beam was collimated into a circular spot of 50
μm in diameter by a metal collimator, and X-ray diffrac-
tion peaks were obtained from a radiated surface area of
approximately 250 μm in diameter. The fixed specimen
was swung and rotated in the appropriate range of Euler
angles to measure the optimal BAp orientation intended
in this study. The detailed conditions used in the micro-
XRD analysis were as described in a previous paper [16].
Preferential alignment of the BAp c-axis was evaluated as
the relative intensity ratio of the (002) diffraction peak to
the (310) peak from the X-ray profile measured in the
cranio-caudal direction.
The L4 specimens were cut perpendicular to the cranio-
caudal axis at the mid point, and the cross sections were
abraded by using emery papers of decreasing grit size from
no. 600, no. 800, no. 1200 to no. 2000 under water to
remove surface damage and roughness until the central
part of the vertebral bodies was revealed. The measure-
ments were repeatedly performed three times in each
specimen with a slight change in position in the ventral
cortical portion on the revealed cross section of L4 (Figure
1).
Statistical Analysis
All data were expressed as the mean ± standard error (SE).
Statistical analysis was performed using analysis of vari-
ance (ANOVA) and Statistic Analysis System (SAS) soft-
ware. The intergroup differences were assessed using the
Student's t test. To examine the additive effects of ALF and
RIS, a two-way ANOVA model of ALF treatment, RIS treat-
ment and interaction between the two drugs was used for
the bone mechanical properties, the microstructural
The regions of pQCT BMD and BAp axis measures in the L4  specimens Figure 1
The regions of pQCT BMD and BAp axis measures in 
the L4 specimens.
measurement
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parameters, the bone resorption marker, the BAp c-axis
orientation and the BMD. The effects of ALF and RIS were
considered to be independent and additive, if the interac-
tion effect was not statistically significant (P > 0.05) in a
two-way ANOVA model, and if the effects of the combina-
tion group were significantly higher than the OVX control
group and each monotherapy group (P < 0.05).
Results
1. Effects on the body weight and the serum and urinary 
biochemical parameters (Table 1)
At the time of necropsy, the average body weight in the
OVX group was significantly higher than that of the Sham
group (p < 0.05), but the administration of both ALF and
RIS did not affect the body weight. Ovariectomy did not
significantly alter the Ca and P levels in serum and urine.
The serum Ca level in the ALF-L + RIS-L group was signif-
icantly higher than that in the RIS-L group or the RIS-H
group (p < 0.05, p < 0.01, respectively). The serum P level
in the ALF-H group was significantly higher than that in
the OVX group (p < 0.05). The serum P level in the RIS-H
group was significantly lower than that in the ALF-L + RIS-
L group (p < 0.05). ALF increased the Ca excretion in a
dose-dependent manner. In contrast, the urinary Ca excre-
tion in the ALF-L + RIS-L group was comparable to that of
the Sham group, and there was a significant difference in
Ca excretion between the ALF-L + RIS-L group and the
ALF-L and the RIS-L groups (p < 0.05 and p < 0.01, respec-
tively). The urinary P excretion in the ALF-H group was
significantly higher than that in the OVX group (p < 0.05).
2. Effects on the bone resorption marker (Figure 2)
Figure 2 shows the level of urinary DPD excretion, a bone
resorption marker. Ovariectomy significantly increased
urinary DPD excretion (p < 0.001), while RIS mono-
therapy decreased the DPD excretion in a dose-dependent
manner. There was a significant difference in DPD excre-
tion between the OVX group and the other three groups:
the ALF-L, ALF-H, and RIS-L groups (p < 0.001). Moreo-
ver, urinary DPD excretion in the ALF-L + RIS-L group was
significantly lower than that in the OVX, ALF-L, and RIS-L
groups (p < 0.001, p < 0.001 and p < 0.001, respectively).
The interaction of ALF and RIS for urinary DPD excretion
was not statistically significant (Table 2). Therefore, with
respect to the suppression of bone resorption, ALF and RIS
were considered to be independent and additive.
3. Effects on the mechanical properties in the fifth lumbar 
vertebra (Figure 3)
Figures 3A, 3B and 3C show the ultimate load, stiffness,
and energy in the lumbar vertebra (L5), respectively.
The ultimate load of the vertebral body in the ALF-H
group was significantly higher than that in the OVX group
(p < 0.01). In the RIS-H group, the ultimate load was sig-
nificantly higher than the OVX and RIS-L groups (p <
0.05, p < 0.01, respectively), indicating that RIS mono-
therapy had a dose-dependent effect on the improvement
of the ultimate load and stiffness in the lumbar vertebra.
However, in the ALF-L+RIS-L group, the ultimate load of
the lumbar vertebra was significantly higher than that in
the OVX group or the RIS-L group (p < 0.01, p < 0.001
respectively). The stiffness in the RIS-H group was signifi-
cantly higher than that in the OVX or RIS-L groups (p <
0.05, p < 0.01, respectively). In the ALF-L + RIS-L group,
the stiffness was significantly higher than that in the OVX
group (p < 0.05). In contrast, there were no significant dif-
ferences among each of the groups with respect to energy
of the vertebral body.
4. Effects on the mechanical properties in the femoral 
midshaft (Figure 4)
Figures 4A, 4B and 4C show the ultimate load, stiffness
and energy in the femoral midshaft, respectively.
The ultimate load, stiffness and energy of the cortical
femur was significantly decreased by ovariectomy (p <
0.001, p < 0.05, and p < 0.01, respectively). ALF mono-
therapy increased the ultimate load and energy of the
femur dose-dependently. In the ALF-H, RIS-L, RIS-H, and
Table 1: Body weight and biochemical parameters
Group n Body weight (g) Serum Ca (mg/dL) Serum P (mg/dL) Urine Ca/CRE Urine P/CRE
Sham 7 388 ± 14* 9.8 ± 0.2 6.1 ± 0.4 0.095 ± 0.038 1.66 ± 0.29
OVX 8 436 ± 13 10.4 ± 0.3 6.7 ± 0.8 0.144 ± 0.072 1.40 ± 0.13
ALF-L 8 469 ± 11 10.6 ± 0.1 6.7 ± 0.4 0.207 ± 0.031a)### 1.73 ± 0.25#
ALF-H 8 447 ± 13 10.1 ± 0.4 6.5 ± 0.2* 0.427 ± 0.040b)** 2.02 ± 0.21*
RIS-L 8 468 ± 10 9.9 ± 0.3a) 5.4 ± 0.2 0.027 ± 0.004b) 1.26 ± 0.11
RIS-H 8 459 ± 11 10.2 ± 0.1b) 5.4 ± 0.1a) 0.027 ± 0.004b) 1.31 ± 0.11
ALF-L + RIS-L 8 465 ± 15 10.7 ± 0.1 5.8 ± 0.1 0.132 ± 0.015## 1.56 ± 0.14
Ca: calcium, P: inorganic phosphate, CRE: creatinine
Mean ± SE (n = 7–8)
*p < 0.05, **p < 0.01 vs. OVX control group
a)p < 0.05, b)p < 0.001 vs. ALF-L+RIS-L group
#p < 0.01, ##p < 0.01, ###p < 0.001 vs. ALF-H groupBMC Musculoskeletal Disorders 2009, 10:66 http://www.biomedcentral.com/1471-2474/10/66
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ALF-L + RIS-L groups, the ultimate load of the femur was
significantly higher than in the OVX group (p < 0.001, p <
0.05, p < 0.001, and p < 0.001, respectively). Furthermore,
the ultimate load in the ALF-L group was significantly
lower than that in the ALF-L + RIS-L and the ALF-H groups
(p < 0.01). The stiffness did not alter with treatment by
any of the drugs. The energy of the femur in the ALF-H,
RIS-L, RIS-H, and ALF-L+RIS-L groups was significantly
higher than in the OVX group (p < 0.01, p < 0.05, p <
0.001, and p < 0.01, respectively). In the ALF-L group, the
energy was significantly lower than that in the ALF-H and
the ALF-L + RIS-L groups (p < 0.05).
5. The microstructural parameters of trabecular bone in 
the fifth lumbar vertebra by micro-CT analysis (Table 3)
Ovariectomy decreased both the bone volume (BV/TV)
and trabecular number (Tb.N), and increased the trabecu-
lar separation (Tb.Sp), suggesting that ovariectomy caused
the cancellous trabecular bone to become thin and sparse,
and disrupted the bone structure. Significant improve-
ments, however, were observed in BV/TV, the bone surface
(BS/BV), Tb.Sp, trabecular thickness (Tb.Th) and Tb.N in
the ALF-H group compared with the OVX group, and RIS
monotherapy did not markedly alter any of the examined
structural parameters. In contrast, ALF monotherapy dose-
dependently ameliorated the structural parameters of
trabecular bone in the lumbar spine. In the ALF-L+RIS-L
group, there were significant improvements in these
microstructural indices compared with the OVX group.
Moreover, the BV/TV, BS/BV, Tb.Th and Tb.N in the ALF-
L+RIS-L group were significantly higher than those in the
ALF-L and the RIS-L groups. The interaction of ALF and
RIS for the structural parameters was not statistically sig-
nificant (Table 4). Therefore, with respect to improvement
of the microstructural parameters of trabecular bone, ALF
and RIS were considered to be independent and additive.
6-1. The material properties in ventral cortical portion of 
the fourth lumbar vertebra (Figure 5-A, B, C)
As shown in Figure 5-A, the BMD of the restricted cortical
volume corresponding to the analyzed portion of the
micro-XRD was significantly lower in the OVX group than
that in the Sham group (p < 0.001). However, in the ALF-
L, ALF-H, ALF-L + RIS-L (p < 0.001) and RIS-L (p < 0.05)
groups, the BMD was significantly higher than that in the
OVX group (Figure 5-A). Figure 5-B shows the intensity
ratio of (002)/(310) corresponding to the orientation
degree of the BAp c-axis in the cranio-craudal direction.
The ratio in randomly oriented apatite powders (calcium
hydroxyapatite; NIST #2910) is about 2, and preferential
alignment of the BAp c-axis in the cranio-craudal direc-
tion increases the ratio. Figure 5-C shows typical
microbeam XRD profiles as a reference. Clear peaks were
obtained regardless of whether the bone had low crystal-
linity. Since the diffraction peaks of (002) and (310) were
relatively isolated from the neighboring peaks, a reliable
intensity ratio of (002)/(310) can be calculated from the
diffraction peaks.
Effect of alfacalcidol and risedronate, alone or in combina- tion, on the bone resorption marker in OVX rats Figure 2
Effect of alfacalcidol and risedronate, alone or in 
combination, on the bone resorption marker in OVX 
rats. Starting 12 weeks after OVX, drugs were administered 
orally to rats for 12 weeks. Urinary DPD excretion was 
measured as biochemical marker of bone resorption, as 
described in MATERIALS AND METHODS. Data for DPD 
are corrected for urinary CRE concentrations. Each value 
represents the mean ± SE (n = 7–8). *p < 0.05, **p < 0.01, 
***p < 0.001 compared with the OVX-control group. Note 
that the combination therapy with ALF and RIS suppressed 
urinary DPD excretion more effectively than each drug 
alone. DPD: deoxypyridinoline, CRE: creatinine.
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Table 2: The effects of ALF and RIS on biomechanical properties 
of bones and urinary DPD excretion
Variable a two-way ANOVA1)
interaction ALF-L RIS-L ALF × RIS
Urinary DPD excretion <0.0001 0.0035 0.2115
L5 ultimate load (N) 0.0001 0.3290 0.1776
L5 stiffness (N/mm) 0.0345 0.1031 0.5763
L5 energy (mJ) 0.9173 0.6353 0.3556
Femur ultimate load (N) 0.0979 <0.0001 0.1821
Femur stiffness (N/mm) 0.5386 0.4792 0.6799
Femur energy (mJ) 0.1358 0.0009 0.6119
1) P values were obtained from a two-way ANOVA model.BMC Musculoskeletal Disorders 2009, 10:66 http://www.biomedcentral.com/1471-2474/10/66
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The intensity ratio of (002)/(310) in the OVX group was
significantly higher than that in the Sham group (p <
0.05), indicating an increase in the anisotropy of the
material parameter, the BAp orientation, by ovariectomy.
The increase in intensity ratio of (002)/(310) by ovariec-
tomy was recovered by RIS-H monotherapy and the com-
bination therapy of ALF-L and RIS-L. In other words, ALF/
RIS combination therapy restored the bone material
parameter, BAp orientation, to the normal state.
6-2. Relationship between the BMD and BAp orientation 
in the cortical portion of the fourth lumbar vertebra 
(Figure 6)
BMD and the BAp orientation are independent parame-
ters for describing bone microstructure because they cor-
respond to the density of BAp and the orientation of the
BAp c-axis, respectively. Thus, a balance between the two
parameters is very important and should be considered.
Figure 6 shows the balance between the BMD and the BAp
orientation in the ventral cortical portion of a lumbar ver-
tebra (L4) using the results in Figures 5-A and 5-B. The
OVX group exhibited lower BMD and higher BAp orienta-
tion than the Sham group, and the treated groups were
located between the OVX group and the Sham group.
Since the normal balance between BMD and BAp orienta-
tion corresponds to that in the Sham group, the optimal
balance should be approaching that in the Sham group.
Higher BAp orientation is not necessarily appropriate and
effective for exerting bone mechanical properties under an
unpredictable fluctuating load because the optimal degree
of BAp orientation must be close to that of the Sham
group. The combination therapy of ALF+RIS showed the
closest balance of BMD/BAp orientation, indicating the
optimal state of the bone material parameters based on
the BMD and the BAp c-axis orientation.
Discussion
In this study, we clearly demonstrated that the combina-
tion treatment of ALF and RIS administered at their
respective sub-therapeutic doses improved the mechani-
cal properties of the lumbar spine and femoral midshaft
in an OVX rat model of osteoporosis by suppression of
bone resorption. The improvement of the material prop-
erties, such as the microstructural parameters and also the
BAp c-axis orientation, contributed to the reinforcement
of mechanical strength in the lumbar spine. Moreover, the
combination treatment of ALF and RIS normalized the
urinary Ca excretion, indicating that this treatment amel-
iorated the changes in Ca metabolism. These findings sug-
gest that the combination treatment of ALF and RIS had a
therapeutic advantage over either the ALF or RIS mono-
therapy for treating osteoporosis.
Effects on the bone mechanical properties of lumbar vertebra in OVX rats Figure 3
Effects on the bone mechanical properties of lumbar vertebra in OVX rats. Starting 12 weeks after OVX, drugs 
were administered orally to rats for 12 weeks. The ultimate load, the stiffness and the energy in the fifth vertebral body were 
determined, as described in MATERIALS AND METHODS. Each value represents the mean ± SE (n = 7–8). **p < 0.01, **p < 
0.01 compared with the OVX-control group. Note that the combination therapy with ALF and RIS increased the ultimate load 
more effectively than RIS alone (p < 0.01).
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Active vitamin D drugs, including ALF, are used to treat
osteoporosis due to their safety and ease of administra-
tion, although higher doses of these agents can cause
hypercalciuria or hypercalcemia. In this study, a high dose
of ALF increased the ultimate load of the lumbar vertebra
and the ultimate load as well as the energy in the femoral
midshaft. The results of detailed micro-CT, micro-XRD
and pQCT analyses indicated that the increase in mechan-
ical strength of the lumbar vertebra after treatment with a
high dose of ALF was primarily due to the restoration of
trabecular bone and the increase in bone density of corti-
cal tissue, whereas ALF did not alter the BAp orientation
in the cortical portion as a candidate of bone quality indi-
ces. These findings demonstrated that ALF monotherapy
improved the mechanical strength of bone by affecting
the density and structural factors. We also observed in the
present study that ALF dose-dependently increased uri-
nary Ca excretion, as a reflection of intestinal Ca absorp-
tion, suggesting that ALF monotherapy caused the
hypercalciuria.
Effects on the bone mechanical properties of femoral midshaft in OVX rats Figure 4
Effects on the bone mechanical properties of femoral midshaft in OVX rats. Starting 12 weeks after OVX, drugs 
were administered orally to rats for 12 weeks. The ultimate load, the stiffness and the energy in the femoral midshaft was 
determined, as described in MATERIALS AND METHODS. Each value represents the mean ± SE (n = 7–8). *p < 0.05, **p < 
0.01, ***p < 0.001 compared with the OVX-control group. Note that the combination therapy with ALF and RIS increased the 
ultimate load and the energy at femoral midshaft more than ALF alone (p < 0.001).
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Table 3: Microarchitectural indices of lumbar vertebra
Group
(/mm)
BV/TV (%) BS/BV (%) Tb.Sp (μm) Tb.Th (μm) Tb.N
Sham 0.36 ± 0.02c) 28.3 ± 0.9 0.124 ± 0.005c) 0.071 ± 0.002 5.1 ± 0.1c)
OVX 0.26 ± 0.02 31.6 ± 1.6 0.190 ± 0.010 0.064 ± 0.003 4.0 ± 0.1
ALF-L 0.27 ± 0.01**## 29.3 ± 0.4*## 0.183 ± 0.005**## 0.068 ± 0.001*## 4.0 ± 0.1**##
ALF-H 0.32 ± 0.01b) 26.7 ± 0.6a) 0.158 ± 0.004a) 0.088 ± 0.002b) 4.3 ± 0.1a)
RIS-L 0.27 ± 0.01* 29.3 ± 0.6* 0.181 ± 0.010 0.068 ± 0.001* 4.0 ± 0.1*
RIS-H 0.29 ± 0.01 28.4 ± 0.5 0.167 ± 0.005 0.071 ± 0.001 4.2 ± 0.1
ALF-L+RIS-L 0.31 ± 0.01a) 27.9 ± 0.3a) 0.157 ± 0.004a) 0.072 ± 0.001a) 4.4 ± 0.1a)
BV/TV: bone volume, BS/BV: bone surface, Tb.Sp: trabecular separation, Tb.Th: trabecular thickness, Tb.N: trabecular number
Mean ± SE (n = 7–8)
a)p < 0.05, b)p < 0.01, c)p < 0.001 vs. OVX control group
*p < 0.05, **p < 0.01 vs. ALF-L+RIS-L group
#p < 0.05, ##p < 0.01 vs. ALF-H groupBMC Musculoskeletal Disorders 2009, 10:66 http://www.biomedcentral.com/1471-2474/10/66
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It has been reported that bisphosphonates increase bone
mass by suppressing bone resorption specifically by
inducing apoptosis of osteoclasts [30]. Bisphosphonates
that contain nitrogen, such as RIS and ALN, significantly
reduce the risk of vertebral and nonvertebral fractures in
patients with osteoporosis [31,32]. However, the clinical
use of bisphosphonates is rather complicated and the
compliance can be low because they are absorbed through
the intestinal tract at extremely low rates and give rise to
gastrointestinal tract disorders. Also, the mechanisms by
which bisphosphonates reduce fractures are not fully
understood. Bone quality can be defined as the sum of all
factors mediating mechanical competence at constant
bone mass. It includes factors such as bone mineral and
matrix tissue properties defining mineralization, turno-
ver, and microdamage, as well as bone geometry, mass
distribution and microarchitecture [33]. Borah B et al.
reported that RIS restored the degree of mineralization
and the ratios of low- to highly-mineralized bone to pre-
menopausal levels after three years of treatment and that
the BV/TV and trabecular architecture examined by micro-
CT analysis did not change from baseline after up to five
years of RIS treatment [34]. It was also reported by Fratzl
P et al. that in postmenopausal osteoporosis the calcium/
vitamin D supplementation increased matrix mineraliza-
tion (without affecting BV/TV) irrespective of three-year
treatment with RIS, suggesting that patients who had low
matrix mineralization at baseline had large increases in
matrix mineralization density due to calcium/vitamin D
supplementation [35].
In the present study, a high dose of RIS increased the ulti-
mate load and energy in the femoral midshaft. This was
consistent with micro-XRD examination of the vertebral
bodies which showed that the BAp c-axis orientation
(which is related to the mechanical function in the cortical
portion of L4) recovered with RIS dosage. However, RIS
had no clear effects on the microstructural parameters in
the trabecular region of the vertebra. For 12 months,
Boyce RW et al. repeatedly administered subcutaneous
injections of RIS at 5 mg/kg/day for 1 week to OVX rats
and then did not administer the drug for the next three
weeks beginning when the rats were 3-months-old. They
found that the number of trabeculae and their connectiv-
ity were significantly increased by this regimen [36]. The
differences between the two studies are probably due to
the regimens by which the drug was administered. Erben
RG et al. investigated the preventive effects of combina-
tion RIS/calcitriol (1α25(OH)D3) therapy by administer-
ing the drugs to 4-month-old rats immediately after
ovariectomy [37]. They had reported that, when these
drugs were administered at monotherapeutic doses previ-
ously shown to suppress the decreases in bone mass and
mechanical strength, they further increased the bone mass
and mechanical strength of lumbar vertebrae and long
bones. Harris ST et al. found in a clinical study that RIS
therapy combined with HRT (which suppresses bone
resorption) increases the non-vertebral BMD more mark-
edly than it increases the vertebral BMD, and suppresses
bone turnover, as indicated by markers of bone metabo-
lism [38]. However, in a recent clinical trial of the effects
of a combination treatment of ALN and recombinant
human PTH (1–84) (a bone formation accelerator) on
BMD, some dose combinations had negligible pharmaco-
logical effects [39]. This indicated that not all combina-
tion therapies are additive toward bone loss. Therefore, it
is necessary to identify the effective combinations and
administration methods not only on bone density but
also bone quality in osteoporosis treatment.
The analysis of bone metabolic markers revealed that,
although ovariectomy accelerated urinary DPD excretion,
the combination therapy of ALF and RIS significantly low-
ered DPD excretion compared to the ALF-L or RIS-L mon-
otherapy, and the interaction was not statistically
significant. It suggested that ALF and RIS suppressed bone
resorption independently and additively. In the lumbar
vertebra, both ALF-L and RIS-L did not significantly alter
the ultimate load and stiffness compared with the OVX
control group. However, in the combination group, both
the ultimate load and the stiffness were significantly
higher than the OVX control group. Also, in the femoral
midshaft, the ultimate load and energy in the combina-
tion group were significantly higher than the OVX control
group, whereas those in the ALF-L group or the RIS-L
group were not different from the OVX control group. Fur-
thermore, in the improvement of the microstructural indi-
ces, ALF and RIS were also considered to be independent
and additive.
In this study, the BMD and BAp axis orientation at ventral
cortical position and the microstructural parameters at
trabecular region were assessed to determine a candidate
for the spinal strength improvement. The BMD was signif-
icantly higher in the ALF-L group or the RIS-L group as
Table 4: The effects of ALF and RIS microstructural indices, 3D-
BMD and BAp c-axis orientation in lumbar vertebra
Variable a two-way ANOVA1)
interaction ALF-L RIS-L ALF × RIS
L5 BV/TV 0.0420 0.0173 0.3994
L5 BS/BV 0.0438 0.0487 0.6317
L5 Tb.N 0.0670 0.0355 0.2750
L5 Tb.Th 0.0352 0.0350 0.8419
L5 Tb.Sp 0.1208 0.0358 0.1493
BAp c-axis orientation 0.2266 0.0599 0.9375
3D-BMD 0.0326 0.8417 0.0020
1) P values were obtained from a two-way ANOVA model.BMC Musculoskeletal Disorders 2009, 10:66 http://www.biomedcentral.com/1471-2474/10/66
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Figure 5 (see legend on next page)
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well as the combination group compared with the OVX
control group. In contrast, the BAp c-axis orientation in
the combination group was significantly lower than the
OVX control group, although those in both the ALF-L
group and the RIS-L group were not changed compared
with the OVX group. Therefore, in the present study, it
seems that the material properties, such as the microstruc-
tural parameters and the BAp c-axis orientation, contrib-
uted to the reinforcement of spinal strength.
In patients with senile osteoporosis, Ca deficiency caused
by low absorption of Ca may be a problem. Although this
Ca deficiency can be corrected by active vitamin D admin-
istration due to facilitation of Ca absorption through the
gastrointestinal tract, such treatment may increase the risk
of hypercalciuria and hypercalcemia. Bisphosphonates
may cause hypocalcemia by suppression of bone resorp-
tion. It also has been reported that bisphosphonates are
cytotoxic to human colon cancer cells, which have been
used in an intestinal epithelial model [40], and thus may
affect Ca channel function. The different mechanisms of
these drugs on bone metabolism suggest that a combina-
tion therapy using an active vitamin D agent with a
bisphosphonate could be particularly effective at reducing
bone loss and simultaneously improving Ca homeostasis
in osteoporosis. Therefore, it is necessary to compare the
effects on Ca absorption and excretion between the ALF +
RIS combination therapy and each monotherapy. In this
study, it was observed that the dose-dependent promo-
tion of urinary Ca excretion by ALF monotherapy was can-
celed by the combination treatment with RIS, and
consequently urinary Ca excretion was maintained at a
normal level. Taken together, the simultaneous adminis-
tration of ALF and RIS at their sub-therapeutic doses
improves the Ca balance, suggesting that the combination
therapy at lower dose may reduce the risk of known
adverse drug reactions by these two drugs alone.
The aim of this study was to determine whether the addi-
tive effects of ALF and RIS combination therapy have
advantages over each monotherapy. Based on our results,
we concluded that: (1) with respect to the improvement
of the mechanical strength of lumbar spine as well as the
femoral midshaft, the combination treatment of ALF and
RIS at their sub-therapeutic doses was more effective than
the each monotherapy; (2) in the suppression of bore
resorption and the amelioration of microstructural
parameters, the effects of ALF and RIS were considered to
be independent and additive; (3) the improvement of
material properties, such as the microstructural parame-
ters and the BAp c-axis orientation, contributed to the
reinforcement of spinal strength; and (4) the combined
therapy of ALF and RIS normalized the urinary Ca excre-
Effects on the BMD and the BAp orientation at the ventral cortical portion of lumbar spine Figure 5 (see previous page)
Effects on the BMD and the BAp orientation at the ventral cortical portion of lumbar spine. Starting 12 weeks 
after OVX, drugs were administered orally to rats for 12 weeks. The BMD (A) and the BAp c-axis orientation (B) in the 
cranio-craudal direction were measured at the ventral cortical portion of the 4th lumbar spine by pQCT and micro-XRD, 
respectively, as described in MATERIALS AND METHODS. Typical micro-XRD profiles of the OVX and Sham rats were 
described for clarifying the spectral quality (C). Each value represents the mean ± SE (n = 7–8). *p < 0.05, ***p < 0.001 com-
pared with the OVX-control group. Note that the combination therapy with ALF and RIS recovers the BAp c-axis orientation 
at the 4th lumbar spine (p < 0.05). Intensity ratio of (002)/(310) corresponds to the orientation degree of the BAp c-axis as a 
bone quality parameter based on a material property in the cranio-craudal direction. The ratio in randomly oriented apatite 
powders is approximately 2, and increase in the preferential alignment of the BAp c-axis in the cranio-craudal direction 
increases the intensity ratio.
Effects on balance of BMD and BAp orientation at the ventral  cortical portion of lumbar spine Figure 6
Effects on balance of BMD and BAp orientation at 
the ventral cortical portion of lumbar spine. Starting 
12 weeks after OVX, drugs were administered orally to rats 
for 12 weeks. The BMD and the BAp orientation were meas-
ured at the ventral cortical portion of the 4th lumbar spine by 
pQCT and maicro-XRD, respectively, as described in MATE-
RIALS AND METHODS. Each value represents the mean ± 
SE (n = 7–8). Note that the combination therapy with ALF 
and RIS promoted to approach to the normal state of the 
Sham group. Intensity ratio of (002)/(310) corresponds to 
the orientation degree of the BAp c-axis as a bone quality 
parameter based on a material property in the cranio-craudal 
direction.
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tion, suggesting that this therapy ameliorated the changes
in Ca metabolism.
Conclusion
These results demonstrate that the combined ALF and RIS
therapy at their sub-therapeutic doses can improve the
mechanical properties of the spine and femur and amelio-
rate Ca metabolism in an animal model of osteoporosis,
suggesting that the combination therapy of ALF and RIS
has a therapeutic advantage over each monotherapy for
the treatment of osteoporosis.
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